An Executive Informational Overview (EIO) is now available on Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies, primarily for rare and orphan diseases, with an initial focus on Sickle Cell Disease (SCD). The 76-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
orphan diseases,
EMMA,
orphan drug,
sickle cell crisis,
The Steve Harvey Show,
emmaus life sciences,
sickle cell disease,
L-glutamine,
endari,
diverticulosis
A 13-page Quarterly Update is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases.
Read More
Topics:
covid19,
coronovirus,
SARS-CoV-2,
galectrin-3,
glycovirology,
bioxytran,
complex carbohydrate chemistry,
galectin
Crystal Research Associates has issued a 17-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19,
monkeypox
An Executive Informational Overview (EIO) is now available on SG Blocks, Inc., a leading developer, designer, and fabricator of modular structures, meeting the growing demand for safe and green construction. The 64-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
SG Blocks,
modular construction,
green building,
COVID-19 testing,
Starbucks,
Taco Bell,
Sanitec,
green construction,
shipping containers,
GreenSteel,
cargo modified modules,
Verizon,
Puma,
Lacoste,
NBA,
Equinox,
Clarity Lab Solutions,
SGBX
An Executive Informational Overview (EIO) is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases. The 70-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
covid19,
coronovirus,
SARS-CoV-2,
galectrin-3,
glycovirology,
bioxytran,
complex carbohydrate chemistry,
galectin
Crystal Research Associates has issued a 19-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19,
monkeypox
An Executive Informational Overview (EIO) is now available on Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The 62-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
cancer,
REQORSA,
genprex,
diabetes,
gene therapy,
non-small cell lung cancer,
small-cell lung cancer
An Executive Informational Overview (EIO) is now available on ImmunoPrecise Antibodies Ltd, a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
biotech,
biopharmaceuticals,
biotechnology,
Oncology,
Biologics,
Humanized monoclonal antibodies,
Immunoassay,
Immunogen,
Monoclonal antibody,
Antibody,
Contract research organization (CRO),
Customer relationship management (CRM),
Human monoclonal antibodies,
SARS-CoV-2,
Polyclonal antibody,
Contract manufacturing organization (CMO),
Enterprise resource planning (ERP)
Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19
Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
cancer,
covid19,
coronovirus,
covid-19
An Executive Informational Overview (EIO) is now available on FSD Pharma Inc., a biopharmaceutical company focused on developing innovative therapies for brain and inflammatory disorders to improve patient quality of life. The 58-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
biotech,
biopharmaceuticals,
biotechnology,
neurodegenerative,
multiple sclerosis,
inflammatory,
MS,
major depressive disorder (MDD),
myelin degradation,
bipilar disorder
An Executive Informational Overview (EIO) is now available on Victory Square Technologies Inc., a publicly-traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6), and the OTCQX (VSQTF). The Company builds, acquires, and invests in promising startups, then provides the senior leadership with resources in which to fast-track a company’s growth, resulting in rapid scale-up and monetization. Victory Square’s sweet spot is the innovative technology that is shaping the Fourth Industrial Revolution, where boundaries are being blurred between the physical, digital, and biological worlds. The 76-page report details the Company's business and key sectors of focus, profiles its 20+ investees, as well as details its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
artificial intelligence (AI),
Augmented reality,
Electronic medical records,
Fourth Industrial Revolution,
Internet of Things,
Metaverse,
Non-fungible tokens,
Web 3.0,
Victory Square Technologies,
Creator Economy,
Software-as-a-Service,
Saas,
Solar photovoltaic,
Unicorn company,
Virtual reality
An Executive Informational Overview (EIO) is now available on Emerald Health Pharmaceuticals Inc., a closely-held clinical-stage biotechnology company developing novel proprietary therapeutic molecules to treat various neurodegenerative, autoimmune, inflammatory, and fibrotic diseases with no current cure. The 74-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Read More
Topics:
biotech,
biopharmaceuticals,
biotechnology,
neurodegenerative,
fibrotic,
multiple sclerosis,
Huntingtons Disease,
cannabigerol,
SSc,
inflammatory,
systemic sclerosis,
MS,
Parkinsons Disease,
cannabinoids,
cannabidiol
Crystal Research Associates has issued a 13-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
zika,
aids/hiv,
hbv,
covid19,
coronovirus
Crystal Research Associates has issued a 6-page update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ) following its announcement of an Assignment and License Agreement with PNP Therapeutics, Inc. (“PNP”), granting GeoVax exclusive rights to develop and commercialize Gedeptin®, a novel patented product to treat solid tumors.
Read More
Topics:
immunotherapy,
malaria,
hemorragic fever,
geovax,
vaccines,
zika,
aids/hiv,
hbv,
covid19,
coronovirus